Comparative analysis of the COVID-19 sequences in India and investigate the trialogue relationship between the miR- NA with Coronavirus and Gut Microbiota

ABSTRACT

Background: The Coronavirus disease 2019 (COVID -19), an infectious disease caused by newly discovered Novel Coro- navirus. COVID-19 has spread worldwide causing a pandemic, with maximum death -cases. Hence there is an urgent need for vaccines and treatments to be developed to combat the COVID -19. To overcome this Micro RNA (miRNA) based therapy will be an effective option in controlling infection. The miRNA is a noncoding single -stranded RNA that is smaller in size (17-24nucleotides). They are also able to regulate the Gut Microbiota, an essential factor of host immune response. The usage of miRNA instead of other techniques has many advantages that include early detection, improved pathogen identification, detection of latent infection, personalized medicine. Methods: Selective COVID 19 genome sequences with special reference from India by NCBI genome database and Nextstrain.org. Coronavirus subtyping and Mutation analysis carried out by Genome Detective Coronavirus Typing Tool (version 1.1.3) and CLUSTAL OMEGA software. The prediction of antiviral miRNA are performed online by Tar- getscan.org Results: This study integrated selective bioinformatics tools and databases to investigate the COVID -19 sequences in India and the trialogue relationship between the miRNA with Coronavirus and Gut Microbiota. The miRNA is found to be a potential biomarker and also therapeutics for diseases in viral diseases. Conclusions: The miRNA has been extensively documented for their key roles in combating the disease and it is still an unexplored area. As the miRNA regulates the gene of the target, altering the expression can bring in a desired therapeu- tic outcome.